Diabetic macular edema treated with intravitreal aflibercept injection after treatment with other anti-VEGF agents (SWAP-TWO study): 6-month interim analysis.
Amy S BabiuchThais F ContiFelipe F ContiFabiana Q SilvaAleksandra RachitskayaAlex YuanRishi P SinghPublished in: International journal of retina and vitreous (2019)
Patients with prior anti-VEGF therapy who were transitioned to IAI therapy revealed significant anatomic improvements through 6 months.Trial registration Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab (SwapTwo), Trial registration number: NCT02559180. Date of registration: September 24, 2015.https://clinicaltrials.gov/ct2/show/NCT02559180.
Keyphrases
- age related macular degeneration
- vascular endothelial growth factor
- study protocol
- endothelial cells
- clinical trial
- phase iii
- diabetic retinopathy
- phase ii
- computed tomography
- randomized controlled trial
- single cell
- magnetic resonance imaging
- ultrasound guided
- newly diagnosed
- positron emission tomography
- image quality
- magnetic resonance
- combination therapy
- placebo controlled